The new monitor will enable doctors, asthma specialists, GPs and respiratory specialists to comply with ATS and ERS guidelines when testing for FENO levels in patients. Adults and young children can be easily tested, correctly assessed and promptly put on the correct drug regime thus saving time and reducing costs.
The accuracy of each test is attributable to the innovative and low cost NObreathFlo™ breath conditioning and sample entrapment system. Ambient levels of NO are removed with an NO specific “scrubber” filter. A humidity filter and simple user feedback ensure a successful sample is taken, measuring NO from the airways. An anti-bacterial filter and one-way valve address infection control issues.
Bedfont Technical Manager Phil Bromley said: “This is a much anticipated new product for Bedfont which will allow FENO monitoring to be available to a far wider population of airway inflammation sufferers. The battery powered monitor has been specifically designed to be highly portable. A large graphical colour touch screen and rapid start-up allows easy use by people of all ages.”
FENO is the first non-invasive, valid marker of airway inflammation, making tests safe, quick and easy. The relation between elevated levels of FENO in exhaled breath and airway inflammation, such as in asthma sufferers, is well established. Orders are now being taken for this new device which will be available from early 2008.
Word Count 247
CONTACT Jennifer Cole, Bedfont Scientific Ltd., Tel: +44 (0)1634 673739
NOTES TO EDITORS
Bedfont Scientific is based in Rochester, Kent. Bedfont is already well established within the respiratory field as world leaders in the support of smoking cessation programmes, using breath carbon monoxide monitors. Their experience of the market and extensive research into airway inflammation has led them to develop an affordable product with these professions in mind.
Healthcare Republic does not have an editorial influence or input in to these press releases. The views expressed within these documents are not endorsed by Healthcare Republic or Haymarket Medical Publications Limited.
Enquiries should be directed to any contacts listed within the press releases.